IMUX vs. ALT

In the year-to-date period, IMUX achieves a 1.00% return, which is significantly higher than ALT's -8.74% return. Over the past 10 years, IMUX has underperformed ALT with an annualized return of -49.33%, while ALT has yielded a comparatively higher -35.05% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Immunic, Inc. (IMUX) and Altimmune, Inc. (ALT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current IMUX Sharpe Ratio is -0.31, which is higher than the ALT Sharpe Ratio of -0.47. The chart below compares the historical Sharpe Ratios of IMUX and ALT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither IMUX nor ALT has paid dividends to shareholders.

The maximum IMUX drawdown since its inception was -99.93%, roughly equal to the maximum ALT drawdown of -99.94%. Use the drawdown chart below to compare losses from any high point for IMUX and ALT. For additional features, visit the drawdowns tool.

The current volatility for Immunic, Inc. (IMUX) is 16.36%, while Altimmune, Inc. (ALT) has a volatility of 20.22%. This indicates that IMUX experiences smaller price fluctuations and is considered to be less risky than ALT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Immunic, Inc. and Altimmune, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.